SOD1 and amyotrophic lateral sclerosis: The treatment was well tolerated, and this trial marked a milestone as one of the first-ever ALS studies where patient genotype (SOD1 mutation) and disease mechanism (gain-of-function of mutant SOD1 protein in a dose-dependent manner) were used to guide therapy selection.